Search Results
159 results found, term="parkinson", center="ALL"
New England
2017
Cavicchioli L, Ferraresso S, Westmoreland S, Kaliyaperumal S, Knight H, Crossan C, Scobie L, Danesi A, Vadori M, Trez D, Badin RA, Hantraye P, Cozzi E
Posttransplant Lymphoproliferative Disorders in Neuronal XenotransplantedMacaques.
Vet Pathol. 2017 Mar;54(2):336-344. doi: 10.1177/0300985816669407. Epub 2016 Oct 1. 2017.
2015
Hallett PJ, Deleidi M, Astradsson A, Smith GA, Cooper O, Osborn TM, Sundberg M, Moore MA, Perez-Torres E, Brownell AL, Schumacher JM, Spealman RD, Isacson O
Successful function of autologous iPSC-derived dopamine neurons followingtransplantation in a non-human primate model of Parkinson's disease.
Cell Stem Cell. 2015 Mar 5;16(3):269-74. doi: 10.1016/j.stem.2015.01.018. Epub2015 Feb 26. 2015.
2014
Sundberg M, Isacson O
Advances in stem-cell--generated transplantation therapy for Parkinson's disease.
Expert Opin Biol Ther. 2014 Apr;14(4):437-53. doi: 10.1517/14712598.2014.876986. 2014.
2013
Sundberg M, Bogetofte H, Lawson T, Jansson J, Smith G, Astradsson A, Moore M, Osborn T, Cooper O, Spealman R, Hallett P, Isacson O
Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons.
Stem Cells. 2013 Aug;31(8):1548-62. doi: 10.1002/stem.1415. 2013.
2011
Deleidi M, Hargus G, Hallett P, Osborn T, Isacson O
Development of histocompatible primate-induced pluripotent stem cells for neural transplantation.
Stem Cells. 2011 Jul;29(7):1052-63. doi: 10.1002/stem.662. 2011.
Oregon
2023
Weiss AR, Bertoglio D, Liguore WA, Brandon K, Templon J, Link J, McBride JL
Reduced D(2) /D(3) Receptor Binding and Glucose Metabolism in a Macaque Model of Huntington's Disease.
Mov Disord. 2023 Jan;38(1):143-147. doi: 10.1002/mds.29271. Epub 2022 Dec 21. 2023.
2020
Joers V, Masilamoni G, Kempf D, Weiss AR, Rotterman TM, Murray B, Yalcin-Cakmakli G, Voll RJ, Goodman MM, Howell L, Bachevalier J, Green SJ, Naqib A, Shaikh M, Engen PA, Keshavarzian A, Barnum CJ, Nye JA, Smith Y, Tansey MG
Microglia, inflammation and gut microbiota responses in a progressive monkeymodel of Parkinson's disease: A case series.
Neurobiol Dis. 2020 Jul 24;144:105027. doi: 10.1016/j.nbd.2020.105027. 2020.
2017
Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, Caldas C, Christie AL, Clark DA, Dowst H, Dry JR, Doroshow JH, Duchamp O, Evrard YA, Ferretti S, Frese KK, Goodwin NC, Greenawalt D, Haendel MA, Hermans E, Houghton PJ, Jonkers J, Kemper K, Khor TO, Lewis MT, Lloyd KCK, Mason J, Medico E, Neuhauser SB, Olson JM, Peeper DS, Rueda OM, Seong JK, Trusolino L, Vinolo E, Wechsler-Reya RJ, Weinstock DM, Welm A, Weroha SJ, Amant F, Pfister SM, Kool M, Parkinson H, Butte AJ, Bult CJ
PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.
Cancer Res. 2017 Nov 1;77(21):e62-e66. doi: 10.1158/0008-5472.CAN-17-0582. 2017.
2015
Bethea CL, Reddy AP
Ovarian steroids regulate gene expression related to DNA repair andneurodegenerative diseases in serotonin neurons of macaques.
Mol Psychiatry. 2015 Dec;20(12):1565-78. doi: 10.1038/mp.2014.178. Epub 2015 Jan 20. 2015.
2013
Mao P, Manczak M, Shirendeb UP, Reddy PH
MitoQ, a mitochondria-targeted antioxidant, delays disease progression andalleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.
Biochim Biophys Acta. 2013 Dec;1832(12):2322-31. doi:10.1016/j.bbadis.2013.09.005. Epub 2013 Sep 19. 2013.
Mao P, Meshul CK, Thuillier P, Reddy PH
Neurotransmitter CART as a New Therapeutic Candidate for Parkinson's Disease.
Pharmaceuticals (Basel). 2013;6(1):108-23. doi: 10.3390/ph6010108. 2013.
Reddy PH
Amyloid beta-induced glycogen synthase kinase 3beta phosphorylated VDAC1 inAlzheimer's disease: implications for synaptic dysfunction and neuronal damage.
Biochim Biophys Acta. 2013 Dec;1832(12):1913-21. doi:10.1016/j.bbadis.2013.06.012. Epub 2013 Jun 28. 2013.
2012
Leak RK, Garbett KA, Dettmer AM, Zhang Z, Mirnics K, Cameron JL
Physical activity is linked to ceruloplasmin in the striatum of intact but notMPTP-treated primates.
Cell Tissue Res. 2012 Dec;350(3):401-7. doi: 10.1007/s00441-012-1488-3. Epub 2012Sep 2. 2012.
Mao P, Meshul CK, Thuillier P, Goldberg NR, Reddy PH
CART peptide is a potential endogenous antioxidant and preferentially localizedin mitochondria.
PLoS One. 2012;7(1):e29343. doi: 10.1371/journal.pone.0029343. Epub 2012 Jan 3. 2012.
Zigmond MJ, Cameron JL, Hoffer BJ, Smeyne RJ
Neurorestoration by physical exercise: moving forward.
Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S147-50. doi:10.1016/S1353-8020(11)70046-3. 2012.
2011
Reddy PH, Reddy TP
Mitochondria as a therapeutic target for aging and neurodegenerative diseases.
Curr Alzheimer Res. 2011 Jun;8(4):393-409. 2011.
Reddy PH, Reddy TP, Manczak M, Calkins MJ, Shirendeb U, Mao P
Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerativediseases.
Brain Res Rev. 2011 Jun 24;67(1-2):103-18. doi:10.1016/j.brainresrev.2010.11.004. Epub 2010 Dec 8. 2011.
2010
Ben-Yehudah A, Easley CA 4th, Hermann BP, Castro C, Simerly C, Orwig KE, Mitalipov S, Schatten G
Systems biology discoveries using non-human primate pluripotent stem and germcells: novel gene and genomic imprinting interactions as well as unique expression patterns.
Stem Cell Res Ther. 2010 Aug 5;1(3):24. doi: 10.1186/scrt24. 2010.
Southwest
2022
Kim J, Daadi EW, Oh T, Daadi ES, Daadi MM
Human Induced Pluripotent Stem Cell Phenotyping and Preclinical Modeling ofFamilial Parkinson's Disease.
Genes (Basel). 2022 Oct 25;13(11). pii: genes13111937. doi:10.3390/genes13111937. 2022.
Oh T, Daadi ES, Kim J, Daadi EW, Chen PJ, Roy-Choudhury G, Bohmann J, Blass BE, Daadi MM
Dopamine D3 receptor ligand suppresses the expression of levodopa-induceddyskinesia in nonhuman primate model of parkinson's disease.
Exp Neurol. 2022 Jan;347:113920. doi: 10.1016/j.expneurol.2021.113920. Epub 2021 Nov 8. 2022.
2019
Daadi MM
Differentiation of Neural Stem Cells Derived from Induced Pluripotent Stem Cells into Dopaminergic Neurons.
Methods Mol Biol. 2019;1919:89-96. doi: 10.1007/978-1-4939-9007-8_7. 2019.
Kim J, Daadi MM
Non-cell autonomous mechanism of Parkinson's disease pathology caused by G2019SLRRK2 mutation in Ashkenazi Jewish patient: Single cell analysis.
Brain Res. 2019 Nov 1;1722:146342. doi: 10.1016/j.brainres.2019.146342. Epub 2019Jul 19. 2019.
2018
Choudhury GR, Daadi MM
Charting the onset of Parkinson-like motor and non-motor symptoms in nonhumanprimate model of Parkinson's disease.
PLoS One. 2018 Aug 23;13(8):e0202770. doi: 10.1371/journal.pone.0202770.eCollection 2018. 2018.
2017
Phillips KA, Ross CN, Spross J, Cheng CJ, Izquierdo A, Biju KC, Chen C, Li S, Tardif SD
Behavioral phenotypes associated with MPTP induction of partial lesions in commonmarmosets (Callithrix jacchus).
Behav Brain Res. 2017 May 15;325(Pt A):51-62. doi: 10.1016/j.bbr.2017.02.010.Epub 2017 Feb 17. 2017.
2016
Grow DA, Simmons DV, Gomez JA, Wanat MJ, McCarrey JR, Paladini CA, Navara CS
Differentiation and Characterization of Dopaminergic Neurons From Baboon Induced Pluripotent Stem Cells.
Stem Cells Transl Med. 2016 Sep;5(9):1133-44. doi: 10.5966/sctm.2015-0073. Epub2016 Jun 24. 2016.
Tulane
2023
Parthasarathy G, Pattison MB, Midkiff CC
The FGF/FGFR system in the microglial neuroinflammation with Borrelia burgdorferi: likely intersectionality with other neurological conditions.
J Neuroinflammation. 2023 Jan 17;20(1):10. doi: 10.1186/s12974-022-02681-x. 2023.
Washington
2021
Kojima Y, May PJ
The Substantia Nigra Pars Reticulata Modulates Error-Based Saccadic Learning inMonkeys.
eNeuro. 2021 Apr 2;8(2). pii: ENEURO.0519-20.2021. doi:10.1523/ENEURO.0519-20.2021. Print 2021 Mar-Apr. 2021.
2019
El-Shamayleh Y, Horwitz GD
Primate optogenetics: Progress and prognosis.
Proc Natl Acad Sci U S A. 2019 Dec 23. pii: 1902284116. doi:10.1073/pnas.1902284116. 2019.
2015
Matesan MC, Cross DJ, Lewis DH, Minoshima S
Differential alterations of dopamine transporter in the striatum and midbrain in patients with parkinsonian syndrome.
Clin Nucl Med. 2015 Mar;40(3):191-4. doi: 10.1097/RLU.0000000000000638. 2015.
Wisconsin
2022
Zinnen AD, Vichich J, Metzger JM, Gambardella JC, Bondarenko V, Simmons HA, Emborg ME
Alpha-synuclein and tau are abundantly expressed in the ENS of the human appendixand monkey cecum.
PLoS One. 2022 Jun 10;17(6):e0269190. doi: 10.1371/journal.pone.0269190.eCollection 2022. 2022.
2021
Mancinelli AM, Vichich JM, Zinnen AD, Hugon AM, Bondarenko V, Metzger JM, Simmons HA, Golos TG, Emborg ME
Acute Exposure to the Food-Borne Pathogen Listeria monocytogenes Does Not Induce alpha-Synuclein Pathology in the Colonic ENS of Nonhuman Primates.
J Inflamm Res. 2021 Dec 22;14:7265-7279. doi: 10.2147/JIR.S337549. eCollection2021. 2021.
Metzger JM, Matsoff HN, Vu D, Zinnen AD, Jones KM, Bondarenko V, Simmons HA, Moore CF, Emborg ME
Myelin Basic Protein and Cardiac Sympathetic Neurodegeneration in NonhumanPrimates.
Neurol Res Int. 2021 Oct 4;2021:4776610. doi: 10.1155/2021/4776610. eCollection2021. 2021.
Tao Y, Vermilyea SC, Zammit M, Lu J, Olsen M, Metzger JM, Yao L, Chen Y, Phillips S, Holden JE, Bondarenko V, Block WF, Barnhart TE, Schultz-Darken N, Brunner K, Simmons H, Christian BT, Emborg ME, Zhang SC
Autologous transplant therapy alleviates motor and depressive behaviors inparkinsonian monkeys.
Nat Med. 2021 Mar 1. pii: 10.1038/s41591-021-01257-1. doi:10.1038/s41591-021-01257-1. 2021.
2020
Metzger JM, Lopez MS, Schmidt JK, Murphy ME, Vemuganti R, Emborg ME
Effects of Cardiac Sympathetic Neurodegeneration and PPARgamma Activation onRhesus Macaque Whole Blood miRNA and mRNA Expression Profiles.
Biomed Res Int. 2020 May 2;2020:9426204. doi: 10.1155/2020/9426204. eCollection2020. 2020.
Metzger JM, Matsoff HN, Zinnen AD, Fleddermann RA, Bondarenko V, Simmons HA, Mejia A, Moore CF, Emborg ME
Post mortem evaluation of inflammation, oxidative stress, and PPARgammaactivation in a nonhuman primate model of cardiac sympathetic neurodegeneration.
PLoS One. 2020 Jan 7;15(1):e0226999. doi: 10.1371/journal.pone.0226999.eCollection 2020. 2020.
Vermilyea SC, Babinski A, Tran N, To S, Guthrie S, Kluss JH, Schmidt JK, Wiepz GJ, Meyer MG, Murphy ME, Cookson MR, Emborg ME, Golos TG
In Vitro CRISPR/Cas9-Directed Gene Editing to Model LRRK2 G2019S Parkinson'sDisease in Common Marmosets.
Sci Rep. 2020 Feb 26;10(1):3447. doi: 10.1038/s41598-020-60273-2. 2020.
Zammit M, Tao Y, Olsen ME, Metzger J, Vermilyea SC, Bjornson K, Slesarev M, Block WF, Fuchs K, Phillips S, Bondarenko V, Zhang SC, Emborg ME, Christian BT
[(18)F]FEPPA PET imaging for monitoring CD68-positive microglia/macrophageneuroinflammation in nonhuman primates.
EJNMMI Res. 2020 Aug 6;10(1):93. doi: 10.1186/s13550-020-00683-5. 2020.
2019
Metzger JM, Emborg ME
Autonomic dysfunction in Parkinson disease and animal models.
Clin Auton Res. 2019 Aug;29(4):397-414. doi: 10.1007/s10286-018-00584-7. Epub2019 Jan 2. 2019.
Resnikoff H, Metzger JM, Lopez M, Bondarenko V, Mejia A, Simmons HA, Emborg ME
Colonic inflammation affects myenteric alpha-synuclein in nonhuman primates.
J Inflamm Res. 2019 May 7;12:113-126. doi: 10.2147/JIR.S196552. eCollection 2019. 2019.
Vermilyea SC, Guthrie S, Hernandez I, Bondarenko V, Emborg ME
alpha-Synuclein Expression Is Preserved in Substantia Nigra GABAergic Fibers ofYoung and Aged Neurotoxin-Treated Rhesus Monkeys.
Cell Transplant. 2019 Apr;28(4):379-387. doi: 10.1177/0963689719835794. Epub 2019Mar 11. 2019.
2018
Metzger JM, Moore CF, Boettcher CA, Brunner KG, Fleddermann RA, Matsoff HN, Resnikoff HA, Bondarenko V, Kamp TJ, Hacker TA, Barnhart TE, Lao PJ, Christian BT, Nickles RJ, Gallagher CL, Holden JE, Emborg ME
In vivo imaging of inflammation and oxidative stress in a nonhuman primate model of cardiac sympathetic neurodegeneration.
NPJ Parkinsons Dis. 2018 Jul 13;4:22. doi: 10.1038/s41531-018-0057-1. eCollection2018. 2018.
Sison SL, Vermilyea SC, Emborg ME, Ebert AD
Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson'sDisease-Relevant Phenotypes.
Curr Neurol Neurosci Rep. 2018 Oct 4;18(12):84. doi: 10.1007/s11910-018-0893-8. 2018.
Vermilyea SC, Emborg ME
In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson'sDisease Pathology.
Stem Cells Dev. 2018 Jul 15;27(14):960-967. doi: 10.1089/scd.2017.0286. Epub 2018Mar 29. 2018.
Vermilyea SC, Emborg ME
The role of nonhuman primate models in the development of cell-based therapiesfor Parkinson's disease.
J Neural Transm (Vienna). 2018 Mar;125(3):365-384. doi:10.1007/s00702-017-1708-9. Epub 2017 Mar 22. 2018.
2017
Emborg ME
Nonhuman Primate Models of Neurodegenerative Disorders.
ILAR J. 2017 Dec 1;58(2):190-201. doi: 10.1093/ilar/ilx021. 2017.
Vermilyea SC, Guthrie S, Meyer M, Smuga-Otto K, Braun K, Howden S, Thomson JA, Zhang SC, Emborg ME, Golos TG
Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Adult CommonMarmoset Fibroblasts.
Stem Cells Dev. 2017 Sep 1;26(17):1225-1235. doi: 10.1089/scd.2017.0069. Epub2017 Jul 24. 2017.
2016
Shultz JM, Resnikoff H, Bondarenko V, Joers V, Mejia A, Simmons H, Emborg ME
Neurotoxin-Induced Catecholaminergic Loss in the Colonic Myenteric Plexus ofRhesus Monkeys.
J Alzheimers Dis Parkinsonism. 2016 Nov;6(6). doi: 10.4172/2161-0460.1000279.Epub 2016 Nov 3. 2016.
2015
Simon DK, Simuni T, Elm J, Clark-Matott J, Graebner AK, Baker L, Dunlop SR, Emborg M, Kamp C, Morgan JC, Ross GW, Sharma S, Ravina B
Peripheral Biomarkers of Parkinson's Disease Progression and PioglitazoneEffects.
J Parkinsons Dis. 2015;5(4):731-6. doi: 10.3233/JPD-150666. 2015.
Vermilyea SC, Emborg ME
alpha-Synuclein and nonhuman primate models of Parkinson's disease.
J Neurosci Methods. 2015 Nov 30;255:38-51. doi: 10.1016/j.jneumeth.2015.07.025.Epub 2015 Aug 3. 2015.
2014
Emborg ME, Hurley SA, Joers V, Tromp do PM, Swanson CR, Ohshima-Hosoyama S, Bondarenko V, Cummisford K, Sonnemans M, Hermening S, Blits B, Alexander AL
Titer and product affect the distribution of gene expression after intraputaminalconvection-enhanced delivery.
Stereotact Funct Neurosurg. 2014;92(3):182-94. doi: 10.1159/000360584. Epub 2014 Jun 12. 2014.
Joers V, Dilley K, Rahman S, Jones C, Shultz J, Simmons H, Emborg ME
Cardiac sympathetic denervation in 6-OHDA-treated nonhuman primates.
PLoS One. 2014 Aug 18;9(8):e104850. doi: 10.1371/journal.pone.0104850.eCollection 2014. 2014.
Joers V, Emborg ME
Modeling and imaging cardiac sympathetic neurodegeneration in Parkinson'sdisease.
Am J Nucl Med Mol Imaging. 2014 Mar 20;4(2):125-59. eCollection 2014. 2014.
Salvatore MF, Disbrow EA, Emborg ME
Peripheral and cognitive signs: delineating the significance of impairedcatecholamine metabolism in Parkinson's disease progression.
J Neurochem. 2014 Oct;131(2):129-33. doi: 10.1111/jnc.12796. Epub 2014 Jul 5. 2014.
2013
Brady ML, Raghavan R, Alexander A, Kubota K, Sillay K, Emborg ME
Pathways of infusate loss during convection-enhanced delivery into the putamennucleus.
Stereotact Funct Neurosurg. 2013;91(2):69-78. doi: 10.1159/000342492. Epub 2013Jan 22. 2013.
Emborg ME, Liu Y, Xi J, Zhang X, Yin Y, Lu J, Joers V, Swanson C, Holden JE, Zhang SC
Induced pluripotent stem cell-derived neural cells survive and mature in thenonhuman primate brain.
Cell Rep. 2013 Mar 28;3(3):646-50. doi: 10.1016/j.celrep.2013.02.016. Epub 2013Mar 14. 2013.
Emborg ME, Zhang Z, Joers V, Brunner K, Bondarenko V, Ohshima S, Zhang SC
Intracerebral transplantation of differentiated human embryonic stem cells tohemiparkinsonian monkeys.
Cell Transplant. 2013;22(5):831-8. doi: 10.3727/096368912X647144. 2013.
Swanson CR, Du E, Johnson DA, Johnson JA, Emborg ME
Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR- gammaAgonist against MPTP.
PPAR Res. 2013;2013:582809. doi: 10.1155/2013/582809. Epub 2013 Oct 2. 2013.
2012
Joers V, Seneczko K, Goecks NC, Kamp TJ, Hacker TA, Brunner KG, Engle JW, Barnhart TE, Nickles RJ, Holden JE, Emborg ME
Nonuniform cardiac denervation observed by 11C-meta-hydroxyephedrine PET in6-OHDA-treated monkeys.
PLoS One. 2012;7(4):e35371. doi: 10.1371/journal.pone.0035371. Epub 2012 Apr 23. 2012.
Ohshima-Hosoyama S, Simmons HA, Goecks N, Joers V, Swanson CR, Bondarenko V, Velotta R, Brunner K, Wood LD, Hruban RH, Emborg ME
A monoclonal antibody-GDNF fusion protein is not neuroprotective and isassociated with proliferative pancreatic lesions in parkinsonian monkeys.
PLoS One. 2012;7(6):e39036. doi: 10.1371/journal.pone.0039036. Epub 2012 Jun 20. 2012.
2011
Bartlett RM, Murali D, Nickles RJ, Barnhart TE, Holden JE, DeJesus OT
Assessment of fetal brain uptake of paraquat in utero using in vivo PET/CTimaging.
Toxicol Sci. 2011 Aug;122(2):551-6. doi: 10.1093/toxsci/kfr104. Epub 2011 May 4. 2011.
Swanson CR, Joers V, Bondarenko V, Brunner K, Simmons HA, Ziegler TE, Kemnitz JW, Johnson JA, Emborg ME
The PPAR-gamma agonist pioglitazone modulates inflammation and inducesneuroprotection in parkinsonian monkeys.
J Neuroinflammation. 2011 Aug 5;8:91. doi: 10.1186/1742-2094-8-91. 2011.
Tromp DP, Adluru N, Alexander AL, Emborg ME
SIMULATING CONVECTION-ENHANCED DELIVERY IN THE PUTAMEN USING PROBABILISTICTRACTOGRAPHY.
Proc IEEE Int Symp Biomed Imaging. 2011 Mar-Apr;2011:787-790. doi:10.1109/ISBI.2011.5872523. Epub 2011 Jun 9. 2011.
Yerkes
2023
Davin A, Chabardes S, Devergnas A, Benstaali C, Gutekunst CN, David O, Torres-Martinez N, Piallat B
Excessive daytime sleepiness in a model of Parkinson's disease improved by low-frequency stimulation of the pedunculopontine nucleus.
NPJ Parkinsons Dis. 2023 Jan 25;9(1):9. doi: 10.1038/s41531-023-00455-7. 2023.
2022
Cabezas R, Martin-Jimenez C, Zuluaga M, Pinzon A, Barreto GE, Gonzalez J
Integrated Metabolomics and Lipidomics Reveal High Accumulation ofGlycerophospholipids in Human Astrocytes under the Lipotoxic Effect of Palmitic Acid and Tibolone Protection.
Int J Mol Sci. 2022 Feb 23;23(5). pii: ijms23052474. doi: 10.3390/ijms23052474. 2022.
Kim J, Wichmann T, Inan OT, DeWeerth SP
Analyzing the Effects of Parameters for Tremor Modulation via Phase-LockedElectrical Stimulation on a Peripheral Nerve.
J Pers Med. 2022 Jan 8;12(1). pii: jpm12010076. doi: 10.3390/jpm12010076. 2022.
Masilamoni GJ, Sinon CG, Kochoian BA, Singh A, McRiner AJ, Leventhal L, Papa SM
Phosphodiesterase 9 inhibition prolongs the antiparkinsonian action of l-DOPA in parkinsonian non-human primates.
Neuropharmacology. 2022 Jul 1;212:109060. doi: 10.1016/j.neuropharm.2022.109060. Epub 2022 Apr 21. 2022.
Vesga-Jimenez DJ, Martin C, Barreto GE, Aristizabal-Pachon AF, Pinzon A, Gonzalez J
Fatty Acids: An Insight into the Pathogenesis of Neurodegenerative Diseases andTherapeutic Potential.
Int J Mol Sci. 2022 Feb 25;23(5). pii: ijms23052577. doi: 10.3390/ijms23052577. 2022.
2021
Barbuti PA, Barker RA, Brundin P, Przedborski S, Papa SM, Kalia LV, Mochizuki H
Recent Advances in the Development of Stem-Cell-Derived Dopaminergic NeuronalTransplant Therapies for Parkinson's Disease.
Mov Disord. 2021 May 8. doi: 10.1002/mds.28628. 2021.
Beck G, Zhang J, Fong K, Mochizuki H, Mouradian MM, Papa SM
Striatal DeltaFosB gene suppression inhibits the development of abnormalinvoluntary movements induced by L-Dopa in rats.
Gene Ther. 2021 Mar 11. pii: 10.1038/s41434-021-00249-7. doi:10.1038/s41434-021-00249-7. 2021.
Bloem BR, Trenkwalder C, Sanchez-Ferro A, Kalia LV, Alcalay R, Chiang HL, Kang UJ, Goetz C, Brundin P, Papa SM
COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End ofthe Tunnel?
J Parkinsons Dis. 2021;11(1):3-8. doi: 10.3233/JPD-212573. 2021.
Bohnen NI, Costa RM, Dauer WT, Factor SA, Giladi N, Hallett M, Lewis SJG, Nieuwboer A, Nutt JG, Takakusaki K, Kang UJ, Przedborski S, Papa SM
Discussion of Research Priorities for Gait Disorders in Parkinson's Disease.
Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28883. 2021.
Lewis SJG, Factor SA, Giladi N, Hallett M, Nieuwboer A, Nutt JG, Przedborski S, Papa SM
Addressing the Challenges of Clinical Research for Freezing of Gait inParkinson's Disease.
Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28837. 2021.
Masilamoni GJ, Weinkle A, Papa SM, Smith Y
Cortical Serotonergic and Catecholaminergic Denervation in MPTP-TreatedParkinsonian Monkeys.
Cereb Cortex. 2021 Sep 14. pii: 6369969. doi: 10.1093/cercor/bhab313. 2021.
Villalba RM, Behnke JA, Pare JF, Smith Y
Comparative Ultrastructural Analysis of Thalamocortical Innervation of thePrimary Motor Cortex and Supplementary Motor Area in Control and MPTP-Treated Parkinsonian Monkeys.
Cereb Cortex. 2021 Mar 2. pii: 6155986. doi: 10.1093/cercor/bhab020. 2021.
2020
Albaugh DL, Huang C, Ye S, Pare JF, Smith Y
Glutamatergic Inputs to GABAergic Interneurons in the Motor Thalamus of Controland Parkinsonian Monkeys.
Eur J Neurosci. 2020 Apr 26. doi: 10.1111/ejn.14763. 2020.
Dyavar SR, Potts LF, Beck G, Shetty BLD, Lawson B, Podany AT, Fletcher CV, Amara RR, Papa SM
Transcriptomic approach predicts a major role for transforming growth factor betatype 1 pathway in L-Dopa-induced dyskinesia in parkinsonian rats.
Genes Brain Behav. 2020 Aug 2. doi: 10.1111/gbb.12690. 2020.
Joers V, Masilamoni G, Kempf D, Weiss AR, Rotterman TM, Murray B, Yalcin-Cakmakli G, Voll RJ, Goodman MM, Howell L, Bachevalier J, Green SJ, Naqib A, Shaikh M, Engen PA, Keshavarzian A, Barnum CJ, Nye JA, Smith Y, Tansey MG
Microglia, inflammation and gut microbiota responses in a progressive monkeymodel of Parkinson's disease: A case series.
Neurobiol Dis. 2020 Jul 24;144:105027. doi: 10.1016/j.nbd.2020.105027. 2020.
Papa SM, Brundin P, Fung VSC, Kang UJ, Burn DJ, Colosimo C, Chiang HL, Alcalay RN, Trenkwalder C
Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders.
Mov Disord Clin Pract. 2020 Apr 16;7(4):357-360. doi: 10.1002/mdc3.12953.eCollection 2020 May. 2020.
Papa SM, Brundin P, Fung VSC, Kang UJ, Burn DJ, Colosimo C, Chiang HL, Alcalay RN, Trenkwalder C
Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders.
Mov Disord. 2020 Apr 6. doi: 10.1002/mds.28067. 2020.
Singh A, Papa SM
Striatal Oscillations in Parkinsonian Non-Human Primates.
Neuroscience. 2020 Sep 6. pii: S0306-4522(20)30568-6. doi:10.1016/j.neuroscience.2020.09.004. 2020.
2019
Beck G, Singh A, Zhang J, Potts LF, Woo JM, Park ES, Mochizuki H, Mouradian MM, Papa SM
Role of striatal DeltaFosB in l-Dopa-induced dyskinesias of parkinsonian nonhumanprimates.
Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18664-18672. doi:10.1073/pnas.1907810116. Epub 2019 Aug 27. 2019.
Caiola M, Devergnas A, Holmes MH, Wichmann T
Empirical analysis of phase-amplitude coupling approaches.
PLoS One. 2019 Jul 9;14(7):e0219264. doi: 10.1371/journal.pone.0219264.eCollection 2019. 2019.
Caiola M, Pittard D, Wichmann T, Galvan A
Quantification of movement in normal and parkinsonian macaques using videoanalysis.
J Neurosci Methods. 2019 Jul 1;322:96-102. doi: 10.1016/j.jneumeth.2019.05.001.Epub 2019 May 2. 2019.
Cho IK, Yang B, Forest C, Qian L, Chan AWS
Amelioration of Huntington's disease phenotype in astrocytes derived fromiPSC-derived neural progenitor cells of Huntington's disease monkeys.
PLoS One. 2019 Mar 21;14(3):e0214156. doi: 10.1371/journal.pone.0214156.eCollection 2019. 2019.
Devergnas A, Caiola M, Pittard D, Wichmann T
Cortical Phase-Amplitude Coupling in a Progressive Model of Parkinsonism inNonhuman Primates.
Cereb Cortex. 2019 Jan 1;29(1):167-177. doi: 10.1093/cercor/bhx314. 2019.
Masilamoni GJ, Smith Y
Group I metabotropic glutamate receptors in the primate motor thalamus:subsynaptic association with cortical and sub-cortical glutamatergic afferents.
Brain Struct Funct. 2019 Nov;224(8):2787-2804. doi: 10.1007/s00429-019-01937-2.Epub 2019 Aug 17. 2019.
Miterko LN, Baker KB, Beckinghausen J, Bradnam LV, Cheng MY, Cooperrider J, DeLong MR, Gornati SV, Hallett M, Heck DH, Hoebeek FE, Kouzani AZ, Kuo SH, Louis ED, Machado A, Manto M, McCambridge AB, Nitsche MA, Taib NOB, Popa T, Tanaka M, Timmann D, Steinberg GK, Wang EH, Wichmann T, Xie T, Sillitoe RV
Consensus Paper: Experimental Neurostimulation of the Cerebellum.
Cerebellum. 2019 Jun 4. pii: 10.1007/s12311-019-01041-5. doi:10.1007/s12311-019-01041-5. 2019.
Swain AJ, Galvan A, Wichmann T, Smith Y
Structural Plasticity of GABAergic and Glutamatergic Networks in the MotorThalamus of Parkinsonian Monkeys.
J Comp Neurol. 2019 Dec 6. doi: 10.1002/cne.24834. 2019.
Villalba RM, Pare JF, Lee S, Lee S, Smith Y
Thalamic degeneration in MPTP-treated Parkinsonian monkeys: impact uponglutamatergic innervation of striatal cholinergic interneurons.
Brain Struct Funct. 2019 Nov 2. pii: 10.1007/s00429-019-01967-w. doi:10.1007/s00429-019-01967-w. 2019.
Wichmann T
Changing views of the pathophysiology of Parkinsonism.
Mov Disord. 2019 Aug;34(8):1130-1143. doi: 10.1002/mds.27741. Epub 2019 Jun 19. 2019.
de Iure A, Napolitano F, Beck G, Quiroga Varela A, Durante V, Sciaccaluga M, Mazzocchetti P, Megaro A, Tantucci M, Cardinale A, Punzo D, Mancini A, Costa C, Ghiglieri V, Tozzi A, Picconi B, Papa SM, Usiello A, Calabresi P
Striatal spreading depolarization: Possible implication in levodopa-induceddyskinetic-like behavior.
Mov Disord. 2019 Jun;34(6):832-844. doi: 10.1002/mds.27632. Epub 2019 Feb 13. 2019.
2018
Beck G, Maehara S, Chang PL, Papa SM
A Selective Phosphodiesterase 10A Inhibitor Reduces L-Dopa-Induced Dyskinesias inParkinsonian Monkeys.
Mov Disord. 2018 May;33(5):805-814. doi: 10.1002/mds.27341. Epub 2018 Mar 6. 2018.
Beck G, Singh A, Papa SM
Dysregulation of striatal projection neurons in Parkinson's disease.
J Neural Transm (Vienna). 2018 Mar;125(3):449-460. doi:10.1007/s00702-017-1744-5. Epub 2017 Jun 15. 2018.
Bhattacharya S, Ma Y, Dunn AR, Bradner JM, Scimemi A, Miller GW, Traynelis SF, Wichmann T
NMDA receptor blockade ameliorates abnormalities of spike firing of subthalamicnucleus neurons in a parkinsonian nonhuman primate.
J Neurosci Res. 2018 Jul;96(7):1324-1335. doi: 10.1002/jnr.24230. Epub 2018 Mar25. 2018.
Jucker M, Walker LC
Propagation and spread of pathogenic protein assemblies in neurodegenerativediseases.
Nat Neurosci. 2018 Oct;21(10):1341-1349. doi: 10.1038/s41593-018-0238-6. Epub2018 Sep 26. 2018.
Masilamoni GJ, Smith Y
Chronic MPTP administration regimen in monkeys: a model of dopaminergic andnon-dopaminergic cell loss in Parkinson's disease.
J Neural Transm (Vienna). 2018 Mar;125(3):337-363. doi:10.1007/s00702-017-1774-z. Epub 2017 Aug 31. 2018.
Masilamoni GJ, Smith Y
Metabotropic glutamate receptors: targets for neuroprotective therapies inParkinson disease.
Curr Opin Pharmacol. 2018 Feb;38:72-80. doi: 10.1016/j.coph.2018.03.004. Epub2018 Mar 30. 2018.
Singh A, Jenkins MA, Burke KJ Jr, Beck G, Jenkins A, Scimemi A, Traynelis SF, Papa SM
Glutamatergic Tuning of Hyperactive Striatal Projection Neurons Controls theMotor Response to Dopamine Replacement in Parkinsonian Primates.
Cell Rep. 2018 Jan 23;22(4):941-952. doi: 10.1016/j.celrep.2017.12.095. Epub 2018Jan 28. 2018.
Villalba RM, Smith Y
Loss and remodeling of striatal dendritic spines in Parkinson's disease: fromhomeostasis to maladaptive plasticity?
J Neural Transm (Vienna). 2018 Mar;125(3):431-447. doi:10.1007/s00702-017-1735-6. Epub 2017 May 24. 2018.
Vuong J, Devergnas A
The role of the basal ganglia in the control of seizure.
J Neural Transm (Vienna). 2018 Mar;125(3):531-545. doi:10.1007/s00702-017-1768-x. Epub 2017 Aug 1. 2018.
Wichmann T, Bergman H, DeLong MR
Basal ganglia, movement disorders and deep brain stimulation: advances madethrough non-human primate research.
J Neural Transm (Vienna). 2018 Mar;125(3):419-430. doi:10.1007/s00702-017-1736-5. Epub 2017 Jun 10. 2018.
Zheng C, Chen G, Tan Y, Zeng W, Peng Q, Wang J, Cheng C, Yang X, Nie S, Xu Y, Zhang Z, Papa SM, Ye K, Cao X
TRH Analog, Taltirelin Improves Motor Function of Hemi-PD Rats Without InducingDyskinesia via Sustained Dopamine Stimulating Effect.
Front Cell Neurosci. 2018 Nov 13;12:417. doi: 10.3389/fncel.2018.00417.eCollection 2018. 2018.
Zheng C, Chen G, Tan Y, Zeng W, Peng Q, Wang J, Cheng C, Yang X, Nie S, Xu Y, Zhang Z, Papa SM, Ye K, Cao X
TRH Analog, Taltirelin Protects Dopaminergic Neurons From Neurotoxicity of MPTPand Rotenone.
Front Cell Neurosci. 2018 Dec 20;12:485. doi: 10.3389/fncel.2018.00485.eCollection 2018. 2018.
2017
Chen G, Nie S, Han C, Ma K, Xu Y, Zhang Z, Papa SM, Cao X
Antidyskinetic Effects of MEK Inhibitor Are Associated with MultipleNeurochemical Alterations in the Striatum of Hemiparkinsonian Rats.
Front Neurosci. 2017 Mar 9;11:112. doi: 10.3389/fnins.2017.00112. eCollection2017. 2017.
Chen E, Pare JF, Wichmann T, Smith Y
Sub-synaptic localization of Cav3.1 T-type calcium channels in the thalamus ofnormal and parkinsonian monkeys.
Brain Struct Funct. 2017 Mar;222(2):735-748. doi: 10.1007/s00429-016-1242-9. Epub2016 Jun 2. 2017.
Han C, Nie S, Chen G, Ma K, Xiong N, Zhang Z, Xu Y, Wang T, Papa SM, Cao X
Intrastriatal injection of ionomycin profoundly changes motor response to l-DOPA and its underlying molecular mechanisms.
Neuroscience. 2017 Jan 6;340:23-33. doi: 10.1016/j.neuroscience.2016.10.033. Epub2016 Oct 19. 2017.
Joers V, Tansey MG, Mulas G, Carta AR
Microglial phenotypes in Parkinson's disease and animal models of the disease.
Prog Neurobiol. 2017 Aug;155:57-75. doi: 10.1016/j.pneurobio.2016.04.006. Epub2016 Apr 20. 2017.
Masilamoni GJ, Groover O, Smith Y
Reduced noradrenergic innervation of ventral midbrain dopaminergic cell groupsand the subthalamic nucleus in MPTP-treated parkinsonian monkeys.
Neurobiol Dis. 2017 Apr;100:9-18. doi: 10.1016/j.nbd.2016.12.025. Epub 2016 Dec30. 2017.
Sharma VD, Mewes K, Wichmann T, Buetefisch C, Willie JT, DeLong M
Deep brain stimulation of the centromedian thalamic nucleus for essential tremor:a case report.
Acta Neurochir (Wien). 2017 May;159(5):789-793. doi: 10.1007/s00701-017-3143-y.Epub 2017 Mar 16. 2017.
2016
Devergnas A, Chen E, Ma Y, Hamada I, Pittard D, Kammermeier S, Mullin AP, Faundez V, Lindsley CW, Jones C, Smith Y, Wichmann T
Anatomical localization of Cav3.1 calcium channels and electrophysiologicaleffects of T-type calcium channel blockade in the motor thalamus of MPTP-treated monkeys.
J Neurophysiol. 2016 Jan 1;115(1):470-85. doi: 10.1152/jn.00858.2015. Epub 2015Nov 4. 2016.
Iskhakova L, Smith Y
mGluR4-containing corticostriatal terminals: synaptic interactions with directand indirect pathway neurons in mice.
Brain Struct Funct. 2016 Dec;221(9):4589-4599. doi: 10.1007/s00429-016-1187-z.Epub 2016 Jan 30. 2016.
Kammermeier S, Pittard D, Hamada I, Wichmann T
Effects of high-frequency stimulation of the internal pallidal segment onneuronal activity in the thalamus in parkinsonian monkeys.
J Neurophysiol. 2016 Dec 1;116(6):2869-2881. doi: 10.1152/jn.00104.2016. Epub2016 Sep 28. 2016.
Singh A, Mewes K, Gross RE, DeLong MR, Obeso JA, Papa SM
Human striatal recordings reveal abnormal discharge of projection neurons inParkinson's disease.
Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):9629-34. doi:10.1073/pnas.1606792113. Epub 2016 Aug 8. 2016.
Snijders AH, Takakusaki K, Debu B, Lozano AM, Krishna V, Fasano A, Aziz TZ, Papa SM, Factor SA, Hallett M
Physiology of freezing of gait.
Ann Neurol. 2016 Nov;80(5):644-659. doi: 10.1002/ana.24778. Epub 2016 Oct 7. 2016.
Walker LC
Proteopathic Strains and the Heterogeneity of Neurodegenerative Diseases.
Annu Rev Genet. 2016 Nov 23;50:329-346. doi: 10.1146/annurev-genet-120215-034943. 2016.
Wichmann T, DeLong MR
Deep Brain Stimulation for Movement Disorders of Basal Ganglia Origin: Restoring Function or Functionality?
Neurotherapeutics. 2016 Apr;13(2):264-83. doi: 10.1007/s13311-016-0426-6. 2016.
2015
Du H, Nie S, Chen G, Ma K, Xu Y, Zhang Z, Papa SM, Cao X
Levetiracetam Ameliorates L-DOPA-Induced Dyskinesia in Hemiparkinsonian RatsInducing Critical Molecular Changes in the Striatum.
Parkinsons Dis. 2015;2015:253878. doi: 10.1155/2015/253878. Epub 2015 Jan 27. 2015.
Galvan A, Devergnas A, Wichmann T
Alterations in neuronal activity in basal ganglia-thalamocortical circuits in theparkinsonian state.
Front Neuroanat. 2015 Feb 5;9:5. doi: 10.3389/fnana.2015.00005. eCollection 2015. 2015.
Gonzales KK, Smith Y
Cholinergic interneurons in the dorsal and ventral striatum: anatomical andfunctional considerations in normal and diseased conditions.
Ann N Y Acad Sci. 2015 Sep;1349:1-45. doi: 10.1111/nyas.12762. Epub 2015 Apr 15. 2015.
Lin X, Shi M, Masilamoni JG, Dator R, Movius J, Aro P, Smith Y, Zhang J
Proteomic profiling in MPTP monkey model for early Parkinson disease biomarkerdiscovery.
Biochim Biophys Acta. 2015 Jul;1854(7):779-87. doi: 10.1016/j.bbapap.2015.01.007.Epub 2015 Jan 22. 2015.
Mathai A, Ma Y, Pare JF, Villalba RM, Wichmann T, Smith Y
Reduced cortical innervation of the subthalamic nucleus in MPTP-treatedparkinsonian monkeys.
Brain. 2015 Apr;138(Pt 4):946-62. doi: 10.1093/brain/awv018. Epub 2015 Feb 12. 2015.
Potts LF, Park ES, Woo JM, Dyavar Shetty BL, Singh A, Braithwaite SP, Voronkov M, Papa SM, Mouradian MM
Dual kappa-agonist/mu-antagonist opioid receptor modulation reduceslevodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease.
Ann Neurol. 2015 Jun;77(6):930-41. doi: 10.1002/ana.24375. Epub 2015 Mar 27. 2015.
Potts LF, Uthayathas S, Greven AC, Dyavarshetty B, Mouradian MM, Papa SM
A new quantitative rating scale for dyskinesia in nonhuman primates.
Behav Pharmacol. 2015 Feb;26(1-2):109-16. doi: 10.1097/FBP.0000000000000084. 2015.
Singh A, Gutekunst CA, Uthayathas S, Finberg JP, Mewes K, Gross RE, Papa SM, Feld Y
Effects of fibroblast transplantation into the internal pallidum onlevodopa-induced dyskinesias in parkinsonian non-human primates.
Neurosci Bull. 2015 Dec;31(6):705-13. doi: 10.1007/s12264-015-1559-z. Epub 2015Sep 15. 2015.
Singh A, Liang L, Kaneoke Y, Cao X, Papa SM
Dopamine regulates distinctively the activity patterns of striatal output neuronsin advanced parkinsonian primates.
J Neurophysiol. 2015 Mar 1;113(5):1533-44. doi: 10.1152/jn.00910.2014. Epub 2014 Dec 10. 2015.
Swanger SA, Vance KM, Pare JF, Sotty F, Fog K, Smith Y, Traynelis SF
NMDA Receptors Containing the GluN2D Subunit Control Neuronal Function in theSubthalamic Nucleus.
J Neurosci. 2015 Dec 2;35(48):15971-83. doi: 10.1523/JNEUROSCI.1702-15.2015. 2015.
Villalba RM, Mathai A, Smith Y
Morphological changes of glutamatergic synapses in animal models of Parkinson'sdisease.
Front Neuroanat. 2015 Sep 25;9:117. doi: 10.3389/fnana.2015.00117. eCollection2015. 2015.
2014
Devergnas A, Pittard D, Bliwise D, Wichmann T
Relationship between oscillatory activity in the cortico-basal ganglia networkand parkinsonism in MPTP-treated monkeys.
Neurobiol Dis. 2014 Aug;68:156-66. doi: 10.1016/j.nbd.2014.04.004. Epub 2014 Apr 21. 2014.
Galvan A, Hu X, Rommelfanger KS, Pare JF, Khan ZU, Smith Y, Wichmann T
Localization and function of dopamine receptors in the subthalamic nucleus ofnormal and parkinsonian monkeys.
J Neurophysiol. 2014 Jul 15;112(2):467-79. doi: 10.1152/jn.00849.2013. Epub 2014 Apr 23. 2014.
Gyoneva S, Shapiro L, Lazo C, Garnier-Amblard E, Smith Y, Miller GW, Traynelis SF
Adenosine A2A receptor antagonism reverses inflammation-induced impairment ofmicroglial process extension in a model of Parkinson's disease.
Neurobiol Dis. 2014 Jul;67:191-202. doi: 10.1016/j.nbd.2014.03.004. Epub 2014 Mar13. 2014.
Potts LF, Wu H, Singh A, Marcilla I, Luquin MR, Papa SM
Modeling Parkinson's disease in monkeys for translational studies, a criticalanalysis.
Exp Neurol. 2014 Jun;256:133-43. doi: 10.1016/j.expneurol.2013.09.014. Epub 2013 Sep 23. 2014.
Smith Y, Galvan A, Ellender TJ, Doig N, Villalba RM, Huerta-Ocampo I, Wichmann T, Bolam JP
The thalamostriatal system in normal and diseased states.
Front Syst Neurosci. 2014 Jan 30;8:5. doi: 10.3389/fnsys.2014.00005. eCollection 2014. 2014.
Uthayathas S, Masilamoni GJ, Shaffer CL, Schmidt CJ, Menniti FS, Papa SM
Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison withrisperidone and mechanistic implications.
Neuropharmacology. 2014 Feb;77:257-67. doi: 10.1016/j.neuropharm.2013.10.015. 2014.
Villalba RM, Wichmann T, Smith Y
Neuronal loss in the caudal intralaminar thalamic nuclei in a primate model ofParkinson's disease.
Brain Struct Funct. 2014 Jan;219(1):381-94. doi: 10.1007/s00429-013-0507-9. Epub 2013 Mar 19. 2014.
2013
Bogenpohl J, Galvan A, Hu X, Wichmann T, Smith Y
Metabotropic glutamate receptor 4 in the basal ganglia of parkinsonian monkeys:ultrastructural localization and electrophysiological effects of activation in the striatopallidal complex.
Neuropharmacology. 2013 Mar;66:242-52. doi: 10.1016/j.neuropharm.2012.05.017.Epub 2012 May 23. 2013.
Lobb CJ, Zaheer AK, Smith Y, Jaeger D
In vivo electrophysiology of nigral and thalamic neurons inalpha-synuclein-overexpressing mice highlights differences from toxin-based models of parkinsonism.
J Neurophysiol. 2013 Dec;110(12):2792-805. doi: 10.1152/jn.00441.2013. Epub 2013 Sep 25. 2013.
Mathai A, Wichmann T, Smith Y
More than meets the eye-myelinated axons crowd the subthalamic nucleus.
Mov Disord. 2013 Nov;28(13):1811-5. doi: 10.1002/mds.25603. Epub 2013 Jul 12. 2013.
Sanders TH, Clements MA, Wichmann T
Parkinsonism-related features of neuronal discharge in primates.
J Neurophysiol. 2013 Aug;110(3):720-31. doi: 10.1152/jn.00672.2012. Epub 2013 May15. 2013.
Sanders TH, Devergnas A, Wichmann T, Clements MA
Canonical Correlation to Estimate the Degree of Parkinsonism from Local FieldPotential and Electroencephalographic Signals.
Int IEEE EMBS Conf Neural Eng. 2013 Nov;2013:158-161. doi:10.1109/NER.2013.6695896. 2013.
Villalba RM, Smith Y
Differential striatal spine pathology in Parkinson's disease and cocaineaddiction: a key role of dopamine?
Neuroscience. 2013 Oct 22;251:2-20. doi: 10.1016/j.neuroscience.2013.07.011. Epub2013 Jul 16. 2013.
2012
Bogenpohl JW, Ritter SL, Hall RA, Smith Y
Adenosine A2A receptor in the monkey basal ganglia: ultrastructural localization and colocalization with the metabotropic glutamate receptor 5 in the striatum.
J Comp Neurol. 2012 Feb 15;520(3):570-89. doi: 10.1002/cne.22751. 2012.
Hadipour-Niktarash A, Rommelfanger KS, Masilamoni GJ, Smith Y, Wichmann T
Extrastriatal D2-like receptors modulate basal ganglia pathways in normal andParkinsonian monkeys.
J Neurophysiol. 2012 Mar;107(5):1500-12. doi: 10.1152/jn.00348.2011. Epub 2011Nov 30. 2012.
Jin XT, Pare JF, Smith Y
GABA transporter subtype 1 and GABA transporter subtype 3 modulate glutamatergic transmission via activation of presynaptic GABA(B) receptors in the rat globus pallidus.
Eur J Neurosci. 2012 Aug;36(4):2482-92. doi: 10.1111/j.1460-9568.2012.08147.x.Epub 2012 May 23. 2012.
Paule MG, Green L, Myerson J, Alvarado M, Bachevalier J, Schneider JS, Schantz SL
Behavioral toxicology of cognition: extrapolation from experimental animal modelsto humans: behavioral toxicology symposium overview.
Neurotoxicol Teratol. 2012 Mar;34(2):263-73. doi: 10.1016/j.ntt.2012.01.008. Epub2012 Jan 28. 2012.
Revuelta GJ, Benatar M, Freeman A, Wichmann T, Jinnah HA, DeLong MR, Factor SA
Clinical subtypes of anterocollis in parkinsonian syndromes.
J Neurol Sci. 2012 Apr 15;315(1-2):100-3. doi: 10.1016/j.jns.2011.11.017. Epub2011 Nov 30. 2012.
Rubin JE, McIntyre CC, Turner RS, Wichmann T
Basal ganglia activity patterns in parkinsonism and computational modeling oftheir downstream effects.
Eur J Neurosci. 2012 Jul;36(2):2213-28. doi: 10.1111/j.1460-9568.2012.08108.x. 2012.
Smith Y, Wichmann T, Factor SA, DeLong MR
Parkinson's disease therapeutics: new developments and challenges since theintroduction of levodopa.
Neuropsychopharmacology. 2012 Jan;37(1):213-46. doi: 10.1038/npp.2011.212. Epub2011 Sep 28. 2012.
Xiang Z, Thompson AD, Jones CK, Lindsley CW, Conn PJ
Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation ofbasal ganglia function and implications for the treatment of Parkinson's disease.
J Pharmacol Exp Ther. 2012 Mar;340(3):595-603. doi: 10.1124/jpet.111.187856. Epub2011 Dec 1. 2012.
2011
Devergnas A, Wichmann T
Cortical potentials evoked by deep brain stimulation in the subthalamic area.
Front Syst Neurosci. 2011 May 13;5:30. doi: 10.3389/fnsys.2011.00030. eCollection2011. 2011.
Galvan A, Hu X, Smith Y, Wichmann T
Localization and pharmacological modulation of GABA-B receptors in the globuspallidus of parkinsonian monkeys.
Exp Neurol. 2011 Jun;229(2):429-39. doi: 10.1016/j.expneurol.2011.03.010. Epub2011 Mar 16. 2011.
Galvan A, Smith Y
The primate thalamostriatal systems: Anatomical organization, functional rolesand possible involvement in Parkinson's disease.
Basal Ganglia. 2011 Nov 1;1(4):179-189. doi: 10.1016/j.baga.2011.09.001. 2011.
Jaeger D, Kita H
Functional connectivity and integrative properties of globus pallidus neurons.
Neuroscience. 2011 Dec 15;198:44-53. doi: 10.1016/j.neuroscience.2011.07.050.Epub 2011 Jul 27. 2011.
Jin XT, Galvan A, Wichmann T, Smith Y
Localization and Function of GABA Transporters GAT-1 and GAT-3 in the BasalGanglia.
Front Syst Neurosci. 2011 Jul 28;5:63. doi: 10.3389/fnsys.2011.00063. eCollection2011. 2011.
Jucker M, Walker LC
Pathogenic protein seeding in Alzheimer disease and other neurodegenerativedisorders.
Ann Neurol. 2011 Oct;70(4):532-40. doi: 10.1002/ana.22615. 2011.
Masilamoni GJ, Bogenpohl JW, Alagille D, Delevich K, Tamagnan G, Votaw JR, Wichmann T, Smith Y
Metabotropic glutamate receptor 5 antagonist protects dopaminergic andnoradrenergic neurons from degeneration in MPTP-treated monkeys.
Brain. 2011 Jul;134(Pt 7):2057-73. doi: 10.1093/brain/awr137. 2011.
She H, Yang Q, Shepherd K, Smith Y, Miller G, Testa C, Mao Z
Direct regulation of complex I by mitochondrial MEF2D is disrupted in a mousemodel of Parkinson disease and in human patients.
J Clin Invest. 2011 Mar;121(3):930-40. doi: 10.1172/JCI43871. 2011.
Smith Y, Surmeier DJ, Redgrave P, Kimura M
Thalamic contributions to Basal Ganglia-related behavioral switching andreinforcement.
J Neurosci. 2011 Nov 9;31(45):16102-6. doi: 10.1523/JNEUROSCI.4634-11.2011. 2011.
Villalba RM, Smith Y
Neuroglial plasticity at striatal glutamatergic synapses in Parkinson's disease.
Front Syst Neurosci. 2011 Aug 23;5:68. doi: 10.3389/fnsys.2011.00068. eCollection2011. 2011.
Villalba RM, Smith Y
Differential structural plasticity of corticostriatal and thalamostriatalaxo-spinous synapses in MPTP-treated Parkinsonian monkeys.
J Comp Neurol. 2011 Apr 1;519(5):989-1005. doi: 10.1002/cne.22563. 2011.
Wichmann T, Dostrovsky JO
Pathological basal ganglia activity in movement disorders.
Neuroscience. 2011 Dec 15;198:232-44. doi: 10.1016/j.neuroscience.2011.06.048.Epub 2011 Jun 22. 2011.